biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sniper007on Feb 13, 2013 6:14pm

182 Views

Post# 20984529

Snail or Hare?

Ok, sorry for any problems I may have caused Jd. I have spoken my peace as have others on the board.

I have removed those previously on "ignore".

The news re: potential FDA fast track approval just catapulted BTI ahead of the competition and brings us so much closer to cashing in our lottery ticket. Seems we may have just avoided potential years in red tape and a ton of cash. What is best is that Transcend is simply a platform.

Is it possible that once/if BT2111 is approved by the FDA that all Transcend conjugates will be fast tracked?

Sniper

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario